⌕
Evotec · EVO · Nasdaq
Tenet 51 · Mixed
Compare
$1.56−1.27%At closeTenet 51 · Mixed
$1.56−0.02 (−1.27%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Evotec (EVO) Earnings Forecast

Analysts expect Evotec (EVO) to lose $0.72 a share in FY26, from the one published estimate as of Nov 16, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice
FY26 consensus EPS
$−0.72
1 analyst
FY27 consensus EPS
$−0.22
1 analyst · low $−0.25, high $−0.20
EPS revisions, 30 days
−11.4%
$−0.65 to $−0.72

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

One analyst covers this company. Every figure on this page is that one person's estimate rather than an average of several, and it moves on one change of mind.

Consensus as of Nov 16, 2026 · we check it nightly

Analysts expect Evotec to earn $0.28 a share in FY30; 1 analyst publishes an estimate for FY30.

Forward P/E · FY26E
n/m
a multiple of a loss is not meaningful
Range · FY26
None
low, high and average are one number
Coverage · FY26
1 · 4
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY26 EPS consensus is $−0.72, a loss that widened 51.8% in 90 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 90 days. One step per nightly change.

−83.9%−35.5%+12.8%FY26 −51.8%FY27 −71.1%Aug 18Nov 16
EPS30 days90 daysshown aboveSince Jul 10
FY261 analyst▼ −11.4%$−0.65 to $−0.72▼ −51.8%$−0.47 to $−0.72▼ −100.6%$−0.36 to $−0.72
FY271 analyst▼ −28.8%$−0.17 to $−0.22▼ −71.1%$−0.13 to $−0.22▼ −272.9%$−0.06 to $−0.22
Dec '261 analyst▲ +30.9%$−0.17 to $−0.12▼ −0.5%$−0.12 to $−0.12▼ −0.5%$−0.12 to $−0.12
Mar '271 analyst1 of 30 days0.0% so far1 of 90 days0.0% so far◆ 0.0%$−0.01 to $−0.01

Contributors at both ends of the window: FY26 2 and 1. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price at last close · consensus as of Nov 16, 2026

EPS is a loss in the years the Street forecasts, and a multiple of a loss is not a price. So the sum switches to EBITDA, from FY27 on, which is the first year the consensus EBITDA is above zero, and waits for your multiple.

Consensus EBITDA · FY28
$0.1B
1 analyst · thin coverage
Multiple · five-year average P/E
17.4×
Average of the fiscal-year P/Es, FY19 to FY21.
×
Receipt · EVO · FY28Nov 16, 2026
Implied, a share
Waiting

We hold no net cash and no diluted share count for this company, so an EBITDA multiple cannot be bridged to a price a share here. The sum stops rather than guessing the bridge.

Drag the multipleShaded: where Evotec's P/E sat at each fiscal year end, FY19 to FY21. Each dot is one year.
5×10×15×20×25×30×35×
5-yr avg 17.4×10-yr median 19.2×

Each point on the line is a multiple, and the flag is the price it implies for FY28. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

Growth over a negative base is not meaningful. Consensus EPS is a loss in FY26, so there is neither a multiple of those earnings to pay nor a rate to grow from.Show the multiple against its own recordHide the multiple record
Trailing P/E at each fiscal year end, FY19 to FY21 · over 3 fiscal years. The mark is the median of the last 3.
1.9× low31.2× high
19.2× median
We hold no trailing multiple for this company today, so nothing marks today on the track.

How much do analysts disagree?

One analyst publishes on each year, so there is no range to draw: the low, the high and the average are one number, and a single mark stands for each year.

FY26E1 analyst
$−0.82 to $−0.68 · $0.14 wide
FY27E1 analyst
$−0.25 to $−0.20 · $0.04 wide
FY28E1 analyst
$0.00 to $0.01 · $0.00 wide
FY29E1 analyst
$0.13 to $0.16 · $0.03 wide
FY30E1 analyst
$0.27 to $0.32 · $0.05 wide

The dashed line is FY25 filed $−0.68, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. Spreads are shown in currency rather than as percentages, because a percentage of a number near zero overstates it.

Is next quarter a high bar or an easy one?

Analysts expect Evotec to lose $0.12 a share in the December quarter, the one estimate published. We hold no expected date for the next report.

Expected report
Not held
No expected date is published for this company's next report, so none is printed here.
Revenue expected · December quarter
$134.4M
2 analysts, 129.4 to 139.0 in $M

For the March quarter, analysts expect a loss of $0.01 a share.

Does Evotec usually beat or miss?

We have not been able to check a quarter yet. Our record of estimates for Evotec begins on Jul 10, 2026, and a quarter can be checked only when we hold an estimate for it from before the company reported.

We started recording estimates on Jul 10, 2026, so quarters that reported before that date cannot be checked.

Our record, one quarter per report
Dec '26not reported yet
Mar '27
Jun '27
Sep '27
Dec '27
Mar '28
Jun '28
Sep '28
Dec '28
Mar '29
Jun '29
Sep '29
Checked so far
None yet
one more every report
Beat expectations
Nothing to count
the first check lands after the next report
Share price reaction
Not held
there is no checked quarter to measure a reaction for
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Evotec on Jul 10, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.

The one analyst covering it expects sales to grow 11.1% in FY27. Consensus EPS is a loss at both ends of that step, so there is no EPS growth rate to take apart.

1 analyst publishes an EPS estimate for FY26 and 4 publish revenue. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
41
FY26E
51
FY27E
11
FY28E
21
FY29E
21
FY30E
The FY26 panel held 2 analysts when our record of it began on Jul 10, 2026 and holds 1 tonight.

The full consensus, year by year

Consensus as of Nov 16, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
0.60.81.1historyStreet forecastFY22FY25FY30E

Coverage thins with distance: 4 revenue estimates for FY26, 2 for FY30.

Diluted EPS · $filed · consensus average · band = low to high
−1.23−0.430.38historyStreet forecastFY22FY25FY30E

Out-year bands widen as fewer analysts publish: 1 EPS estimates for FY26, 1 for FY30.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY25Filed0.9—−0.68————as filed—
FY26E0.60.6 to 0.7▼34.6%a−0.72−0.82 to −0.68n/ca−0.1−0.30.364 · 1n/m
FY27E0.70.6 to 0.7▲11.1%−0.22−0.25 to −0.20—0.0−0.10.365 · 1n/m
FY28E0.80.7 to 0.8n/cb0.000.00 to 0.01—0.10.00.361 · 1315.4×
FY29E0.80.8 to 0.9n/cb0.140.13 to 0.16—0.20.00.362 · 111.3×
FY30E0.90.9 to 1.0▲14.8%0.280.27 to 0.32▲104.6%0.30.10.362 · 15.5×

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over that year's filed EPS, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 1 EPS estimates for FY26, 4 for revenue. Not investment advice.

What do analysts expect Evotec to earn in FY26?

The one analyst covering Evotec expects it to lose $0.72 a share in FY26, as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.